ImmuCell develops, manufactures and markets animal health biologics for calf health and cattle productivity. Its primary product line, First Defense, uses colostrum-derived, orally delivered antibodies to provide Immediate Immunity against principal viral and bacterial causes of scours in newborn dairy and beef calves.
Company announcements commonly address preliminary product sales, unaudited financial results, manufacturing efficiency, commercial expansion, and the strategic focus on the First Defense franchise. Other recurring developments include board composition, committee structure, senior employment agreements, and updates tied to the paused investment in Re-Tain and related asset use.
ImmuCell Corporation (Nasdaq: ICCC) announced that the FDA has issued a Technical Section Incomplete Letter concerning its New Animal Drug Application (NADA) for Re-Tain®. The letter pertains to the Chemistry, Manufacturing and Controls (CMC) Technical Section submitted earlier this year, with a focus on the need for a successful pre-approval re-inspection of the manufacturing facility. The company is preparing for this re-inspection and intends to submit a response in the upcoming quarter. Importantly, the FDA comments did not raise concerns about the safety or efficacy of Re-Tain®.
ImmuCell Corporation (Nasdaq: ICCC) announced preliminary, unaudited sales for Q2 2022, reporting $3.9 million, a 15% decrease from $4.5 million in Q2 2021. For the six-month period, sales rose to $9.9 million, up 14% from $8.6 million year-over-year. A supply disruption limited production, contributing to a backlog of $704,000. The company is focused on expanding manufacturing capacity and is seeking FDA approval for the new treatment Re-Tain®. A conference call for full Q2 results is scheduled for August 12, 2022.
ImmuCell Corporation (Nasdaq: ICCC) announced its 2022 Annual Meeting of Stockholders will be held virtually on June 15, 2022, at 3:00 PM ET, due to COVID-19 precautions. Stockholders of record as of April 14, 2022, can participate via live audio webcast or telephone. Voting in advance is encouraged. The Company also urged investors to review their recent Form 10-Q filed on May 12, 2022, for insights into financial performance. ImmuCell focuses on improving dairy and beef cattle health through innovative products like First Defense® and Re-Tain®.
ImmuCell Corporation (Nasdaq: ICCC) reported a significant 46% increase in Q1 2022 product sales, reaching $6 million, compared to $4.1 million in Q1 2021. This surge has enhanced cash flows and net income, which stood at $736,000 or $0.09 per diluted share. Gross margins improved to 52%. The company has ramped up production capacity and anticipates an FDA response regarding Re-Tain® by Q3 2022. Cash reserves rose to $11.8 million, while net working capital reached $15.9 million, reflecting a healthy financial position.
ImmuCell Corporation (Nasdaq: ICCC) will announce its unaudited financial results for the quarter ending March 31, 2022, after market close on May 12, 2022. A conference call is scheduled for May 13, 2022, at 9:00 AM ET to discuss the results. Dr. Joseph H. Crabb will participate to cover the company's science and technology. The Quarterly Report on Form 10-Q will be available post-market close on May 12, 2022, along with a corporate presentation on ImmuCell's business.
ImmuCell Corporation (Nasdaq: ICCC) has appointed Dr. Mark Wustenberg as the new Commercial Leader of Stakeholder Engagement, aimed at launching their innovative product, Re-Tain®, pending FDA approval. Dr. Wustenberg brings significant experience in the dairy industry, having held various leadership roles, including at Tillamook County Creamery. His focus will be on enhancing communication and research efforts to foster product acceptance, benefiting both Re-Tain® and the First Defense® product line. The company is set to discuss its financial results on May 13, 2022.
ImmuCell Corporation (Nasdaq: ICCC) has appointed Dr. Mark Wustenberg as Commercial Leader of Stakeholder Engagement. Dr. Wustenberg brings extensive experience from his previous roles, including Vice President of Sustainability at Tillamook County Creamery. He will focus on the upcoming launch of Re-Tain®, pending FDA approval, and enhancing the market presence of First Defense®. The company aims to improve dairy producer profitability through these initiatives, leveraging Dr. Wustenberg's industry expertise to strengthen its sales and marketing strategy.
ImmuCell Corporation (Nasdaq: ICCC) reported preliminary, unaudited sales of $6.0 million for Q1 2022, a 46% increase from $4.1 million in Q1 2021. This marks a record high for any quarter. The company is expanding its First Defense manufacturing capacity from $16.5 million to $35 million, with annualized output reaching $23.8 million. ImmuCell is also awaiting FDA approval for the Re-Tain product, with a response expected in Q3 2022.
ImmuCell Corporation (Nasdaq: ICCC) reported a strong performance for the year ended December 31, 2021, with product sales increasing by 25% to $19.2 million compared to 2020. In Q4 alone, sales surged by 45% to $5.4 million. The company's gross margin improved to 47% for Q4 and 45% for the year. Net operating income shifted to a gain of $257,000, contrasting with a $1.4 million loss in 2020. Cash and equivalents rose to $10.2 million. A significant FDA submission regarding Re-Tain is expected to impact future market launch plans.
ImmuCell Corporation (Nasdaq: ICCC) plans to announce its unaudited financial results for Q4 and the year ended December 31, 2021, on February 22, 2022. A conference call will be held on February 23, 2022, at 9:00 AM ET, where executives will discuss production capacity investments for the First Defense product line and insights regarding the upcoming launch of Re-Tain.
The Annual Report on Form 10-K is expected to be filed by March 30, 2022. Stakeholders are encouraged to view the updated corporate presentation on the company's website following the financial results announcement.